EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

Hendrik Dinkel iD, Linus Materna, Ramona Stelmach iD, Stefanie Zschäbitz, Stephanie Neuberger, Can D Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff und 10 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70267 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Hendrik Dinkel und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Ipilimumab, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ipilimumab and nivolumab are recommended as first‐line therapy for patients with metastatic or advanced renal cell carcinoma (aRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk. We retrospectively evaluated efficacy and safety in a multi‐center real‐world cohort with 356 patients initiating ipilimumab and nivolumab from 17 centers in Germany and Switzerland. Median age was 64 years, most patients were male (69.1%) and had clear cell histology (74.1%). IMDC risk was intermediate in 61.8% and poor in 28.7%. About 37.1% of cases did not meet the inclusion criteria for the CheckMate 214 pivotal study (e.g., poor Eastern Cooperative Oncology Group [Performance Status Scale] [ECOG] status, comorbidities, brain metastases, and impaired renal function). After a median follow‐up of 17.5 months, complete response was seen in 8.7%, partial response in 28.7% of patients. Median progression‐free survival (PFS) was 8 (95% confidence interval [CI] 5.4–10.6) and median overall survival (OS) 39 months (95% CI 27.5–50.5). Subgroup analysis of patients with non‐clear cell histology showed a shorter PFS and OS. Other negative predictors were poor ECOG, fewer induction cycles, ineligibility to pivotal study, and hepatic metastases. Adverse events occurred in 76.4% of patients (35.4% ≥ grade 3). High‐dose corticosteroids were applied in 27.3% of cases. Cabozantinib was most frequently administered (63.4%) as subsequent therapy and showed superior OS and PFS compared to other second‐line options. Our data support ipilimumab and nivolumab as a first‐line treatment of aRCC with robust efficacy and safety. Patient selection was less restrictive in our clinical practice and may explain differences to CheckMate 214 trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellIpilimumabKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAged, 80 and overAdultGermanySwitzerlandProgression-Free Survival

Stichwörter der Autor:innen

immunotherapyipilimumabnivolumabreal‐worldrenal cell carcinoma

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Urology, University Hospital Münster, Münster, Germany.
  • Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Interdisciplinary Working Group Kidney Cancer of the German Cancer Society (IAGN-DKG).
  • Department of Urology and Pediatric Urology, University Medical Center of Johannes Gutenberg University, Mainz, Germany.
  • Department of Urology, LMU University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
  • Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany.

ORCID-Profile: Hendrik Dinkel, Ramona Stelmach

Zitieren

APA

Dinkel, H., Materna, L., Stelmach, R., Zschäbitz, S., Neuberger, S., Aydogdu, C. D., Casuscelli, J., Egenolf, T., Silberg, M., Steinestel, J., Strauss, A., Kirchhoff, F., Ahrens, M., Paffenholz, P., Cathomas, R., Özdemir, B. C., Gossler, C., Ivanyi, P., Rehlinghaus, M., …, & Schlack, K. (2026). Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group. International Journal of Cancer. https://doi.org/10.1002/ijc.70267

Vancouver

Dinkel H, Materna L, Stelmach R, Zschäbitz S, Neuberger S, Aydogdu CD, et al. Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group. International Journal of Cancer. 2026. doi:10.1002/ijc.70267

BibTeX
@article{Dinkel2026,
  author = {Dinkel, Hendrik and Materna, Linus and Stelmach, Ramona and Zschäbitz, Stefanie and Neuberger, Stephanie and Aydogdu, Can D and Casuscelli, Jozefina and Egenolf, Timo and Silberg, Matteo and Steinestel, Julie and Strauss, Arne and Kirchhoff, Florian and Ahrens, Marit and Paffenholz, Pia and Cathomas, Richard and Özdemir, Berna C and Gossler, Christopher and Ivanyi, Philipp and Rehlinghaus, Marc and Hilser, Thomas and Grünwald, Viktor and Schlack, Katrin},
  title = {Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70267}
}
Kostenlos starten →